Skip to main content

Table 1 Baseline characteristics of patients

From: Caffeine discontinuation improves acute migraine treatment: a prospective clinic-based study

  Abstinence group (N = 36) Non-abstinence group (N = 72) P
Baseline    
Age, y 41.0 (35.3 – 53.8) 44.0 (37.0 – 55.0) 0.379
Females 30 (83.3 %) 54 (75.0 %) 0.326
BMI, kg/m2 21.3 (19.5 – 24.4) 22.8 (20.5 – 24.6) 0.141
Disease duration, years 10.0 (4.8 – 21.0) 4.5 (2.0 – 10.0) 0.010
Type of primary headache    0.637
 Migraine without aura 26 (72.2 %) 55 (76.4 %)  
 Migraine with aura 10 (27.8 %) 17 (23.6 %)  
Chronic migraine 12 (33.3 %) 21 (29.2 %) 0.658
Allodynia (ASC ≥3) 9 (25.0 %) 15 (22.1 %) 0.735
Headache days (/month) 9.0 (3.0 – 20.0) 9.0 (4.0 – 25.0) 0.546
Severity of headache (numeric rating scale) 7.0 (6.1 - 8.5) 7.0 (6.0 - 8.3) 0.967
HIT-6 score 63.0 (60.0 – 67.5) 60.0 (56.0 – 65.0) 0.018
Pretreatment HADS score 14.0 (11.5 – 17.0) 13.0 (10.0 – 20.0) 0.888
Psychiatric comorbidity    
 Depression 9 (36.0 %) 20 (46.5 %) 0.398
 Anxiety disorder 12 (46.2 %) 16 (37.2 %) 0.463
Estimated dose of caffeinated drinks (mg/day) 192.0 (96.0 – 192.0) 192.0 (96.0 – 288.0) 0.285
Prophylactic medication 25 (34.7 %) 17 (47.2 %) 0.209
 Topiramate 5 (13.9 %) 5 (6.9 %) 0.241
 Beta-blockers 12 (33.3 %) 15 (20.8 %) 0.157
 Calcium channel blockers 14 (38.9 %) 11 (15.3 %) 0.006
 Antidepressants 11 (30.6 %) 17 (23.6 %) 0.438
Antiemetics combination 25 (69.4 %) 49 (68.1 %) 0.884
Follow-up    
Follow-up interval (days) 31.0 (28.0 – 84.3) 35.0 (20.3 – 87.5) 0.894
Estimated dose of caffeinated drinks during follow-up (mg/day) 0.0 (0.0 – 0.0) 96.0 (96.0 – 168.0) <0.001
 <200   54 (75.0 %)  
 ≥200   18 (25.0 %)  
Headache days in the last month 8.5 (4.0 – 15.0) 7.0 (3.0 – 12.0) 0.330
Severity of headache (numeric rating scale) 5.5 (4.0 - 7.0) 6.0 (4.8 - 7.0) 0.117
Acute medication use in the last month 5.0 (4.0 – 10.0) 5.0 (3.5 – 7.5) 0.369
HIT-6 score a 59.0 (52.0 – 65.0) 60.0 (55.0 – 62.0) 0.547
HIT-6 improvement a 5.0 (1.0 – 10.0) 2.0 (-2.3 – 7.0) 0.085
ACT score 4.0 (2.3 – 4.0) 3.0 (1.0 – 4.0) 0.002
ACT = 4 26 (72.2 %) 29 (40.3 %) 0.002
  1. Values are presented as N (%) or median (interquartile range)
  2. Abbreviations: SD standard deviation, BMI body mass index, HADS headache depression and anxiety scale, HIT-6 headache impact test-6, ACT assessment of current treatment
  3. a HIT-6 scores were compared only in 79 patients with follow-up of >1 month